OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Vogelzang Discusses the Addition of Chemotherapy to ADT in Men With Prostate Cancer

June 9th 2014

Nicholas J. Vogelzang, MD,discusses results from the phase III CHAARTED (E3805) study that examined the addition of chemotherapy to androgen deprivation therapy (ADT) for the treatment of men with newly diagnosed metastatic, hormone-sensitive prostate cancer.

Dr. Dispenzieri Discusses Anti-CD38 Monoclonal Antibodies in Myeloma

June 6th 2014

Angela Dispenzieri, MD, a professor of medicine in the division of hematology at the Mayo Clinic, discusses excitement over the development of CD38-targeted monoclonal antibodies as treatments for patients with multiple myeloma.

Dr. Figlin on Advances in Immunotherapy for Kidney Cancer

June 6th 2014

Robert Figlin, MD, FACP, Professor of Medicine and Biomedical Sciences, Steven Spielberg Family Chair in Hematology Oncology, Cedars-Sinai Medical Center, discusses recent advances in the field of immunotherapy for kidney cancer.

Dr. Berenson Discusses Results from the CHAMPION-1 Trial

June 6th 2014

James R. Berenson, MD, founder, President and Medical and Scientific Director of the Institute for Myeloma and Bone Cancer Research, President of Oncotherapeutics, discusses the dose-escalation portion of the phase I/II CHAMPION-1 study looking at weekly carfilzomib in combination with dexamethasone for patients with relapsed or refractory multiple myeloma.

Dr. Ramalingam on the Results of the Phase III REVEL Study in NSCLC

June 5th 2014

Suresh S. Ramalingam, MD, a professor of medical oncology at the Winship Cancer Institute of Emory University in Atlanta, Georgia, discusses the results of the phase III REVEL study in NSCLC.

Dr. Wolchok on Ipilimumab After Complete Resection of Stage III Melanoma

June 5th 2014

Jedd D. Wolchok, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, Giant of Cancer Care, discusses the initial efficacy and safety results from the EORTC 18071 phase III trial, which looked at ipilimumab versus placebo after complete resection of stage III melanoma.

Dr. Curran on the Effect of Clinical Trial Enrollment on NSCLC Patients

June 4th 2014

Walter J. Curran, Jr, MD, discusses a report that examined the effect of institutional clinical trial enrollment volume on survival of patients with stage III non-small cell lung cancer (NSCLC) treated with chemoradiation.

Dr. Seetharamu on Immunotherapy Treatment for Head and Neck Cancers

May 27th 2014

Nagashree Seetharamu, MD, assistant professor, Medicine (Hematology and Medical Oncology), Perlmutter Cancer Center at NYU Langone, discusses the possibility of using immunotherapy agents to treat head and neck cancers.

Dr. White Describes the BR-002 Trial in Breast Cancer

May 22nd 2014

Julia White, MD, professor, director, Breast Radiation Oncology, vice chair, Clinical Research, The Ohio State University Comprehensive Cancer Center, describes the BR-002 trial for patients with breast cancer.

Dr. Beer on the Immune-Related Adverse Events of Ipilimumab in mCRPC

May 16th 2014

Tomasz Beer, MD, FACP, professor of medicine, deputy director of the Knight Cancer Institute, Oregon Health and Science University, characterizes the immune-related adverse events associated with ipilimumab in a phase III metastatic castration-resistant prostate cancer trial.

Dr. Litzow on New Immunologic Therapies in ALL

May 15th 2014

Mark R. Litzow, MD, a professor of Medicine in the Division of Hematology at the Mayo Clinic in Rochester, Minnesota, discusses novel immunologic therapies for the treatment of patients with acute lymphoblastic leukemia (ALL).

Dr. Richter on Pomalidomide as Sickle Cell Disease Treatment

May 14th 2014

Joshua Richter, MD, hematologist/oncologist, multiple myeloma, John Theurer Cancer Center, discusses using the FDA-approved multiple myeloma drug pomalidomide to treat patients with sickle cell disease.

Dr. Bendell on a Study of Onartuzumab Plus Bevacizumab for mCRC

May 13th 2014

Johanna Bendell, MD, discusses the rationale of a phase II trial looking at onartuzumab (MetMAb) and bevacizumab for patients with metastatic colorectal cancer (mCRC).

Dr. Rosenberg Discusses the Curative Potential of Cancer Immunotherapy

May 13th 2014

Steven A. Rosenberg, MD, PhD, Chief of Surgery at the National Cancer Institute, discusses the curative potential of immunotherapy for patients with cancer.

Dr. Muss Discusses Evaluating Cardiac Toxicity in Patients With Breast Cancer

May 12th 2014

Hyman B. Muss, MD, professor of oncology, University of North Carolina, director, Geriatric Oncology, Lineberger Comprehensive Cancer Center, discusses evaluating cardiac toxicity in patients with breast cancer.

Dr. Berenson on Weekly Carfilzomib For Patients With R/R Multiple Myeloma

May 9th 2014

James R. Berenson, MD, discusses a phase I study presented at the 2013 ASH meeting that analyzed the use weekly carfilzomib for patients with R/R multiple myeloma.

Dr. Kuerer on the Overtreatment of DCIS

May 9th 2014

Henry M. Kuerer, MD, PhD, FACS, professor of surgery, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, discusses the overtreatment of DCIS.

Dr. Donato Discusses the National Marrow Donor Program

May 8th 2014

Michele L. Donato, MD, medical director, Blood and Marrow Collection Facility, John Theurer Cancer Center (JTCC), provides an overview of the National Marrow Donor Program (NMDP).

Dr. Krishnamurthi on CAPTEM as Treatment for Neuroendocrine Tumors

May 8th 2014

Smitha Krishnamurthi, MD, a medical oncologist and associate professor of medicine at University Hospitals Case Medical Center and Case Western Reserve University, discusses a prospective phase II study of capecitabine and temozolomide (CAPTEM) for progressive, moderately, and well-differentiated metastatic neuroendocrine tumors.

Dr. Salerno on Donations to Breast Cancer Research

May 7th 2014

Judith A. Salerno, MD, MS, president, CEO, Susan G. Komen, comments on donations to breast cancer research.